Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Amazon Explores AI Content Marketplace With Media Publishers 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
NEW YORK, April 09, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Henry Schein, Inc. ("Henry Schein") (NASDAQ:HSIC) securities between March 7, 2013 and February 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/henry-schein-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Henry Schein was engaging in unethical, anti-competitive behavior through agreements with Benco Dental Supply Company and Patterson Companies, Inc., in violation of United States antitrust laws; (2) Henry Schein engaged in such behavior, in part, to help maintain profitability in a consolidating health care industry; (3) these violations of U.S. antitrust laws would result in heightened scrutiny by the federal government and a lawsuit filed by the Federal Trade Commission (“FTC”); (4) Henry Schein failed to maintain adequate internal controls; and (5) as a result, defendants' statements about Henry Schein’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Henry Schein you have until May 7, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/henry-schein-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
